Detail akcie Myriad Genetics online

Business Summary: Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Myriad Genetics Inc revenues decreased 2% to $824.5M. Net loss increased from $127.3M to $365.9M. Revenues reflect Rest of world segment decrease of 17% to $56.5M, United States segment decrease of less than 1% to $768M. Higher net loss reflects Genetic testing segment loss increase from $123.5M to $387.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.41 to -$3.95.